The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months ...

Despite being more likely to be diagnosed with triple negative breast cancer (TNBC), Black women remain underrepresented in ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm ...

| When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from ...

Radiopharmaceuticals are transforming modern medicine, while simultaneously intensifying the pressures on pharmaceutical ...